Xilio Therapeutics Inc (XLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -45,396 | -29,109 | -13,265 | -58,241 | -45,148 |
| Depreciation Amortization | 1,218 | 878 | 497 | 1,644 | 1,268 |
| Accounts payable and accrued liabilities | -276 | 1,522 | -590 | 1,526 | -76 |
| Other Working Capital | 16,881 | 34,432 | 39,395 | 33,302 | 32,970 |
| Other Operating Activity | 24,579 | 6,778 | 2,941 | 3,391 | 6,765 |
| Operating Cash Flow | $-2,994 | $14,501 | $28,978 | $-18,378 | $-4,221 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -423 | -423 | -22 | -36 | -30 |
| Investing Cash Flow | $-423 | $-423 | $-22 | $-36 | $-30 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -3,382 | -3,382 |
| Common Stock Issued | 51,909 | 52,194 | 4,832 | 32,578 | 24,376 |
| Financing Cash Flow | $51,909 | $52,194 | $4,832 | $29,196 | $20,994 |
| Beginning Cash Position | 57,073 | 57,073 | 57,073 | 46,291 | 46,291 |
| End Cash Position | 105,565 | 123,345 | 90,861 | 57,073 | 63,034 |
| Net Cash Flow | $48,492 | $66,272 | $33,788 | $10,782 | $16,743 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,994 | 14,501 | 28,978 | -18,378 | -4,221 |
| Capital Expenditure | -423 | -423 | -22 | -36 | -30 |
| Free Cash Flow | -3,417 | 14,078 | 28,956 | -18,414 | -4,251 |